Scarica l'app Stockscreener
0.26
3.64%
-0.0118
Precedente Chiudi:
$0.2718
Aprire:
$0.2638
Volume 24 ore:
283.50K
Relative Volume:
0.20
Capitalizzazione di mercato:
$16.82M
Reddito:
$1.16M
Utile/perdita netta:
$-39.74M
Rapporto P/E:
-0.4194
EPS:
-0.62
Flusso di cassa netto:
$-35.02M
1 W Prestazione:
-6.66%
1M Prestazione:
-0.04%
6M Prestazione:
+53.97%
1 anno Prestazione:
-91.30%
Intervallo 1D:
$0.259
$0.2696
Intervallo di 1 settimana:
$0.2526
$0.2906
Portata 52W:
$0.1406
$3.18
Glycomimetics Inc Stock (GLYC) Company Profile
Nome
Glycomimetics Inc
Settore
Industria
Telefono
240-243-1201
Indirizzo
9708 MEDICAL CENTER DRIVE, ROCKVILLE, MD
Confronta GLYC con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
GLYC
Glycomimetics Inc
|
0.2601 | 16.82M | 1.16M | -39.74M | -35.02M | -0.62 |
|
VRTX
Vertex Pharmaceuticals Inc
|
490.10 | 124.35B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
689.62 | 75.07B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
633.30 | 37.96B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
242.00 | 31.79B | 2.25B | -278.16M | -42.59M | -2.17 |
|
BNTX
Biontech Se Adr
|
112.82 | 27.34B | 3.30B | -501.07M | 1.03B | -2.1146 |
Glycomimetics Inc Stock (GLYC) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2024-07-26 | Downgrade | TD Cowen | Buy → Hold |
| 2023-12-22 | Iniziato | CapitalOne | Overweight |
| 2021-11-12 | Aggiornamento | Jefferies | Hold → Buy |
| 2019-11-14 | Iniziato | ROTH Capital | Buy |
| 2019-08-05 | Downgrade | Jefferies | Buy → Hold |
| 2019-08-05 | Downgrade | Piper Jaffray | Overweight → Neutral |
| 2019-08-05 | Downgrade | SunTrust | Buy → Hold |
| 2019-04-12 | Iniziato | Piper Jaffray | Overweight |
| 2018-12-18 | Iniziato | H.C. Wainwright | Buy |
| 2016-07-26 | Iniziato | SunTrust | Buy |
| 2015-03-17 | Reiterato | Stifel | Buy |
Mostra tutto
Glycomimetics Inc Borsa (GLYC) Ultime notizie
GlycoMimetics, Inc. Announces Board Resignations -February 25, 2025 at 05:00 pm EST - Marketscreener.com
StockNews.com Begins Coverage on GlycoMimetics (NASDAQ:GLYC) - Defense World
GlycoMimetics Says Following Termination, Co Will Not Have Any Material Financial Or Other Obligations Under Agreement - TradingView
GlycoMimetics ends key agreement; board members, executives depart By Investing.com - Investing.com South Africa
GlycoMimetics ends key agreement; board members, executives depart - Investing.com
GlycoMimetics Faces Leadership Changes Amid Board Resignations - TipRanks
US Penny Stocks To Watch In February 2025 - Yahoo Finance
GlycoMimetics, Inc. (NASDAQ:GLYC) Short Interest Update - Defense World
Why GCL Global Holdings Shares Are Trading Higher By Around 107%; Here Are 20 Stocks Moving Premarket - Benzinga
GlycoMimetics (NASDAQ:GLYC) Coverage Initiated at StockNews.com - Defense World
Top 5 Biotech Stocks That Got Most Retail Buzz Last Week - NewsBreak
GlycoMimetics adjusts merger terms with Crescent Biopharma - MSN
GlycoMimetics And GENFIT Announce Significant Agreement Amendments - Evrim Ağacı
GlycoMimetics adjusts merger terms with Crescent Biopharma By Investing.com - Investing.com UK
GLYCOMIMETICS INC SEC 10-K Report - TradingView
GlycoMimetics (NASDAQ:GLYC) Now Covered by Analysts at StockNews.com - Defense World
Glycomimetics, Inc. Announces Cessation of Brian Hahn as Chief Financial Officer, No Later Than March 31, 2025 - Marketscreener.com
Glycomimetics, Inc. Announces Cessation of Harout Semerjian as Chief Executive Officer, No Later Than March 31, 2025 - Marketscreener.com
Reviewing PureTech Health (NASDAQ:PRTC) and GlycoMimetics (NASDAQ:GLYC) - Defense World
StockNews.com Initiates Coverage on GlycoMimetics (NASDAQ:GLYC) - Defense World
GlycoMimetics executives to depart amid merger plans By Investing.com - Investing.com South Africa
GlycoMimetics executives to depart amid merger plans - MSN
Should You Buy GlycoMimetics (GLYC) Ahead of Earnings? - MSN
GlycoMimetics and Crescent Biopharma Update Investor Presentation in Connection with Proposed Merger - Defense World
GlycoMimetics and Crescent Biopharma Announce Merger Plans - Yahoo Finance
Avacta Appoints Brian Hahn as Chief Financial Officer - The Manila Times
Avacta Appoints Brian Hahn as Chief Financial Officer - GlobeNewswire Inc.
GlycoMimetics (NASDAQ:GLYC) Earns Sell Rating from Analysts at StockNews.com - Defense World
Is It Time For Me To Buy GlycoMimetics Inc (NASDAQ: GLYC) Stock Now? - Stocks Register
GlycoMimetics Receives Extension Notice from Nasdaq Regarding Minimum Bid Price ComplianceOn December 19, 2024, GlycoMimetics, Inc. (NASDAQ: GLYC) disclosed in an 8-K filing with the Securities and Exchange Commission that it had received an e - Defense World
GlycoMimetics, Inc. announced that it expects to receive $200 million in funding - Marketscreener.com
GlycoMimetics (NASDAQ:GLYC) Now Covered by StockNews.com - Defense World
GlycoMimetics skyrockets on buyout deal - MSN
Logos Global Management LP Acquires 5 Million Shares in GlycoMim - GuruFocus.com
GlycoMimetics: Q3 Earnings Snapshot - Darien Times
Crescent Biopharma to Present at Jefferies London Healthcare Conference 2024 - Quantisnow
Crescent Biopharma to Showcase Cancer Drug Pipeline at Jefferies Healthcare Conference - StockTitan
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates ZUO, PFIE, GLYC on Behalf of Shareholders - The Malaysian Reserve
Finansavisen - Finansavisen
RA Capital Management's Strategic Acquisition of GlycoMimetics I - GuruFocus.com
GlycoMimetics Announces New Uproleselan Clinical Data Will Be Presented at ASH Annual Meeting - BioSpace
Glycomimetics Inc Azioni (GLYC) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Glycomimetics Inc Azioni (GLYC) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Invus Public Equities, L.P. | 10% Owner |
Aug 07 '24 |
Sale |
0.18 |
61,488 |
11,197 |
6,578,438 |
| Invus Public Equities, L.P. | 10% Owner |
Aug 05 '24 |
Sale |
0.19 |
164,523 |
30,996 |
6,695,658 |
| Invus Public Equities, L.P. | 10% Owner |
Aug 06 '24 |
Sale |
0.18 |
55,732 |
10,188 |
6,639,926 |
| Invus Public Equities, L.P. | 10% Owner |
Aug 02 '24 |
Sale |
0.20 |
286,200 |
57,354 |
6,860,181 |
| Invus Public Equities, L.P. | 10% Owner |
Aug 01 '24 |
Sale |
0.22 |
63,564 |
13,743 |
7,146,381 |
| Invus Public Equities, L.P. | 10% Owner |
Jul 30 '24 |
Sale |
0.22 |
756,835 |
167,185 |
7,209,945 |
| Invus Public Equities, L.P. | 10% Owner |
Jul 29 '24 |
Sale |
0.24 |
363,949 |
85,637 |
7,966,780 |
| Invus Public Equities, L.P. | 10% Owner |
Jul 26 '24 |
Sale |
0.24 |
258,335 |
62,440 |
8,330,729 |
| Rock Edwin | Chief Medical Officer |
Jun 20 '24 |
Buy |
0.25 |
190,000 |
48,108 |
565,403 |
| Rock Edwin | Chief Medical Officer |
Jun 21 '24 |
Buy |
0.27 |
115,000 |
30,716 |
680,403 |
4.34%
1.68%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):